Breaking News

Q’Apel Medical Launches Armadillo – A New Radial Artery Access Platform to Meet the Needs of Physicians and Patients
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today the launch of the Armadillo Radial Access System, the latest application of the SelectFlex™ technology and part of the SelectFlex™ Family of Neurovascular access systems.
The Armadillo Radial Access System addresses the needs of both physicians and patients in a growing trend to move from femoral artery access to radial artery access. Radial artery access has been the preferred method of access in cardiovascular procedures for decades sighting improved safety profiles and increased comfort for patients. As the demand for radial artery access in neurovascular procedures increases, Q’Apel has positioned itself to lead the way. Armadillo is a radial platform of access catheters specifically designed to address the needs and challenges of radial access.
More Neurointerventionalists are converting to TRA due to the safety profile of this type of access and patient satisfaction.
Pascal M. Jabbour MD, FAANS, FAHA, Distinguished Professor of Neurological Surgery at Thomas Jefferson University Hospital:
With the launch of Armadillo, we find ourselves at the forefront of technological innovations that can bring a paradigm shift in the neurovascular industry. At Q’Apel, everything comes back to the clinicians we serve. From our earliest beginnings, we have built tools not merely out of curiosity but out of demand. We have seen and heard the shortcomings doctors face with other products out there—and we are exceptionally focused on creating solutions that work.
King Nelson, CEO, Q’Apel Medical:
The Armadillo radial platform was designed to do more with less. It offers stable access with fewer catheters and a lower profile than a typical 8F Tri-Axial setup. The key features and benefits of this design can help make a challenging case easier.
Jeff Krolik, CTO, Q’Apel Medical:
Q’Apel Medical products are already being utilized in over 185 hospital systems nationwide. Q’Apel is in the process of significantly increasing its manufacturing capacity and just recently announced moving into a 35,000 square foot facility to accommodate the growth. In addition, the company is in the process of acquiring CE certification, which will allow Q’Apel to expand into Europe later this year.
Companies In This Post
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more